BNXT (BNXT) News
Track canonical SquawkNews coverage tagged to BNXT, BNXT. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BioNxt advances sublingual everolimus ODF for transplant rejection study
BioNxt Solutions Inc. says it is advancing its proprietary sublingual everolimus oral dissolving film (ODF) for organ transplant rejection, and has initiated a large-animal pharmacokinetic study.
EQUITY | Sep 08, 2026, 07:05 AM UTC
L
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Cl
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
EQUITY | Aug 26, 2026, 07:05 AM UTC
L
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
VANCOUVER, BC / / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:B
EQUITY | Jul 06, 2026, 07:05 AM UTC
L
BNXT: Closes Private Placement
BioNxt announces closing of non-brokered private placement of units
EQUITY | Jun 23, 2026, 09:20 PM UTC